Benchmarking therapeutic drug monitoring software: A review of available computer tools

Clinical Pharmacokinetics

Volumn 52, Issue 1, 2013, Pages 9-22

  Fuchs, Aline ^a   Csajka, Chantal ^a,c   Thoma, Yann ^b   Buclin, Thierry ^a   Widmer, Nicolas ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF APPLIED SCIENCES WESTERN SWITZERLAND   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE; AMINOPHYLLINE; CARBAMAZEPINE; CEFTAZIDIME; CHOLINE THEOPHYLLINATE; CYCLOSPORIN A; DIGOXIN; ENFUVIRTIDE; EVEROLIMUS; GENTAMICIN; IMATINIB; INDINAVIR; KANAMYCIN; LITHIUM; NETILMICIN; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; QUINIDINE; RAPAMYCIN; RITONAVIR; STREPTOMYCIN; TACROLIMUS; THEOPHYLLINE; TOBRAMYCIN; VALPROIC ACID; VANCOMYCIN; ZIDOVUDINE;

AGE; BAYESIAN LEARNING; BODY WEIGHT; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; MICROCOMPUTER; PRIORITY JOURNAL; REVIEW; SEX;

BAYES THEOREM; COSTS AND COST ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INFORMATION STORAGE AND RETRIEVAL; MODELS, BIOLOGICAL; SOFTWARE; USER-COMPUTER INTERFACE;

EID: 84873048566     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0020-y     Document Type: Review

References (53)

1. Buclin T, Gotta V, Fuchs A, et al. Monitoring drug therapy. Br J Clin Pharmacol. 2012;73(6):917-23.
2. Platt DR. Individualization of drug dosage regimens. Clin Lab Med. 1987;7(2):289-99.
3. International Association of Therapeutic Drug monitoring and Clinical Toxicology. Definition of TDM. http://www.iatdmct.org/index.php/publisher/ articleview/frmArticleID/138/. Accessed 1 Dec 2011.
4. Burton M, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics & pharmacodynamics. principles of therapeutic drug monitoring. 4th edn. Baltimore: Lippincott Williams & Wilkins; 2006.
5. Durieux P, Trinquart L, Colombet I, et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2008;3:CD002894.
6. Kunz J, Shortliffe EH, Buchanan BG, et al. Computer-assisted decision making in medicine. J Med Philos. 1984;9(2):135-60.
7. Bates D, Soldin SJ, Rainey PM, et al. Strategies for physician education in therapeutic drug monitoring. Clin Chem. 1998;44(2):401-7.
8. Anderson PO. Clinical pharmacokinetics computer programs. In: Anderson PO, McGuinness SM, Bourne PE, editors. Pharmacy informatics. Boca Raton: CRC Press Inc.; 2010. p. 199-216.
9. Frist WH. Shattuck Lecture: health care in the 21st century. N Engl J Med. 2005;352(3):267-72.
10. Special report: health care and technology. Medicine goes digital. The Economist 2009 Apr 16.
11. Guiducci C, Temiz Y, Leblebici Y, et al. Integrating Bio-sensing functions on CMOS chips. 2010 Asia Pacific Conference on Circuits and Systems, Kuala Lumpur, 6-9 Dec 2010.
12. Buffington DE, Lampasona V, Chandler MHH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet. 1993;25(3):205-16.
13. Lenert LA, Klostermann H, Coleman RW, et al. Practical computer-assisted dosing for aminoglycoside antibiotics. Antimicrob Agents Chemother. 1992;36(6):1230-5.
14. Peck CC, Sheiner LB, Martin CM, et al. Computer-assisted digoxin therapy. N Engl J Med. 1973;289(9):441-6.
15. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411-59.
16. Hatton RC, Gotz VP, Robinson JD, et al. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results. Clin Pharm. 1983;2 (4):347-52.
17. Gougnard T, Charlier C, Plomteux G. "CAPCIL": posologic adjustment of aminoglycoside treatments [in French]. Acta Clin Belg Suppl. 1999;1:17-9.
18. Lacarelle B, Pisano P, Gauthier T, et al. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Int J Biomed Comput. 1994;36(1-2):127-30.
19. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22(3):155-63.
20. Bourne D. Pharmacokinetic and pharmacodynamic resources. Pharmacokinetic software. http://www.pharmpk.com/soft.html. Accessed 3 Apr 2012.
21. Jelliffe RW. The USC PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care. 1991;922-4.
22. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol. 1997;43(2):125-35.
23. Robinson JD, Hatton RC, Russell WL, et al. Accuracy of serum gentamicin concentration predictions generated by a personal-computer software system. Clin Pharm. 1984 Sep-Oct;3(5):509-16.
24. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011;32(2):72-81.
25. Gervasini G, Benitez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755-74.
26. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
27. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62(10):1481-502.
28. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metab Drug Interact. 2004;20(4):195-217.
29. Corti N, Taegtmeyer AB. Clinically important food-drug interactions: what the practitioner needs to know [in German]. Praxis. 2012;101(13):849-55.
30. Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006;45(4):365-83.
31. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16(4):253-62.
32. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34(1):57-77.
33. Debord J, Voultoury JC, Lachatre G, et al. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients. Int J Biomed Comput. 1994;36(1-2):135-7.
34. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28(8):743-51.
35. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48(9):1081-91.
36. Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit. 2012;34(4):368-77.
37. Wright DF, Duffull SB. Development of a Bayesian forecasting method for warfarin dose individualization. Pharm Res. 2011;28(5):1100-11.
38. Bjorkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011;17(1):e239-40.
39. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol. 1999;48(1):9-13.
40. Neef C, Jelliffe RW, van Laar T, et al. Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. Int J Biomed Comput. 1994;36(1-2):143-50.
41. Gauthier T, Lacarelle B, Marre F, et al. Predictive performance of two software packages (USC PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. Int J Biomed Comput. 1994;36(1-2):131-4.
42. Norris RL, Martin JH, Thompson E, et al. Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit. 2010;32(5):615-23.
43. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited; 2010. http://www.tg.org.au/index.php? sectionid=41. Accessed 29 Oct 2012.
44. Gotta V, Widmer N, Montemurro M, et al. Therapeutic drug monitoring of imatinib: bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187-201.
45. Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34(4):265-79.
46. Touw D, Neef C, Thomson AH, et al. Cost-effectiveness of therapeutic drug monitoring: an update. EJHP Sci. 2007;13(4):83-91.
47. Shenfield GM. Therapeutic drug monitoring beyond 2000. Br J Clin Pharmacol. 2001;52(Suppl 1):3S-4S.
48. Murphy JE, Slack MK, Campbell S. National survey of hospital-based pharmacokinetic services. Am J Health Syst Pharm. 1996;53(23):2840-7.
49. Pedersen CA, Schneider PJ, Santell JP, et al. ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education, and wellness-2000. Am J Health Syst Pharm. 2000;57(23):2171-87.
50. Elin RJ. Computer-assisted therapeutic drug monitoring. Clin Lab Med. 1987;7(2):485-92.
51. Nieuwlaat R, Connolly SJ, Mackay JA, et al. Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision maker-researcher partnership systematic review. Implement Sci. 2011;6:90.
52. Bates DW. Improving the use of therapeutic drug monitoring. Ther Drug Monit. 1998;20(5):550-5.
53. Special report: health care and technology. Fantastic voyage: technology is making health care more portable, precise and personal. The Economist 2009 Apr 16.